SUPN
Supernus Pharmaceuticals Inc

2,371
Mkt Cap
$3.16B
Volume
224,456.00
52W High
$59.68
52W Low
$29.16
PE Ratio
-80.55
SUPN Fundamentals
Price
$54.77
Prev Close
$55.09
Open
$54.70
50D MA
$50.73
Beta
0.56
Avg. Volume
926,103.52
EPS (Annual)
-$0.6829
P/B
2.98
Rev/Employee
$1.07M
$2,527.32
Loading...
Loading...
News
all
press releases
Envestnet Asset Management Inc. Sells 63,513 Shares of Supernus Pharmaceuticals, Inc. $SUPN
Envestnet Asset Management Inc. reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 70.2% in the 3rd quarter, according to its most recent filing with the...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Given Consensus Rating of "Hold" by Analysts
Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) have earned an average rating of "Hold" from the seven brokerages that are currently covering the firm, MarketBeat.com...
MarketBeat·1d ago
News Placeholder
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 2.6% in the third quarter, according to the company in its most recent filing with the...
MarketBeat·3d ago
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday...
MarketBeat·3d ago
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 12-Month High - Time to Buy?
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High - Still a Buy...
MarketBeat·6d ago
News Placeholder
Supernus Pharmaceuticals Q4 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported fourth-quarter and full-year 2025 results on Monday, highlighting record revenue, expanding contributions from its growth products, and progress...
MarketBeat·7d ago
News Placeholder
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·7d ago
News Placeholder
Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +228.57% and +7.57%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Posts Quarterly Earnings Results, Misses Expectations By $0.48 EPS
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.07) earnings per share for the quarter...
MarketBeat·7d ago
News Placeholder
Bethany Sensenig Sells 4,475 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at...
MarketBeat·8d ago
<
1
2
...
>

Latest SUPN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.